FDA Warning Letters Surged 50%. Here's Why It Matters
A free whitepaper from LabLynx on why regulatory enforcement is accelerating and how the right systems keep your lab audit-ready every day
The Audit Landscape Has Changed. Is Your Lab Ready?
FDA enforcement is not slowing down, it is accelerating. Warning letters from the Center for Drug Evaluation and Research rose 50% in fiscal year 2025. Of 470 warning letters issued last year, 469 cited documentation or records management failures rather than scientific errors. ISO/IEC 17025:2025 adds explicit new requirements for digital records and data integrity. And the FDA's internal AI system now analyzes compliance data to flag high-risk facilities before an inspector arrives. This whitepaper breaks down what has changed, why it matters, and how continuous audit readiness keeps your lab out of the warning list.
What You'll Walk Away With
Five Findings on the Warning List
Why data integrity gaps, records management failures, and broken chain of custody drive nearly every FDA citation.
Why Enforcement Is Intensifying
What the FDA's AI targeting system, ISO/IEC 17025:2025, and the ILAC-IAF merger mean for accredited labs.
The True Cost of a Warning Letter
Between $250K and $1.2M per response, plus 6 to 18 months of lost productivity across your lab.
LIMS as Continuous Compliance
How automated audit trails, embedded SOPs, and unbroken chain of custody make audits routine, not crises.
Get the Whitepaper
Enter your details and download instantly.
"*" indicates required fields